Content
03/20/2025
Oxford United Kingdom
Brainomix
completed $18 million Series C Round funding. Investors include
Boehringer Ingelheim Venture Fund (lead), Parkwalk Advisors (lead), Hostplus.
About
Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for enhanced treatment decisions in stroke and lung fibrosis. With origins as a spinout from the University of Oxford, it is now expanding at a commercial-stage with offices in the UK, Ireland and the USA, and operations in more than 20 countries.
Startup
Sector:
AI
Life Science
Software
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
